00:44 , Apr 15, 2017 |  BioCentury  |  Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
02:25 , Nov 11, 2015 |  BC Extra  |  Financial News

Financial tracks

Apposite Capital named Anne-Laure Meynier investment manager. Most recently, Meynier was CFO at tech start-up Nuage Labs (Paris, France). Prior to that, she was an executive on Bridgepoint's investment team and a member of the...
03:24 , Jan 13, 2015 |  BC Extra  |  Company News

Biogen converges on Convergence

Biogen Idec Inc. (NASDAQ:BIIB) will acquire neuropathic pain play Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) for $200 million up front. Convergence shareholders are eligible for up to $475 million in undisclosed milestones. Convergence's lead compound CNV1014802...
03:24 , Jan 13, 2015 |  BC Extra  |  Company News

Biogen converges on Convergence

Biogen Idec Inc. (NASDAQ:BIIB) will acquire neuropathic pain play Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) for $200 million up front. Convergence shareholders are eligible for up to $475 million in undisclosed milestones. Convergence's lead compound CNV1014802...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Remiges' pipeline remedy

Taiho Pharmaceutical Co. Ltd. and Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) are each pumping $30 million into new VC firm Remiges Ventures to get more exposure to early stage research. According to a July SEC...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Financial News

RuiYi completes venture financing

RuiYi Inc. , La Jolla, Calif.   Business: Autoimmune, Cancer   Date completed: 3/27/14   Type: Venture financing   Raised: $15 million   Investors: 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; Aravis...
00:50 , Mar 28, 2014 |  BC Extra  |  Financial News

RuiYi raises $15 million in B round

RuiYi Inc. (La Jolla, Calif.) raised $15 million in a series B round from existing investors 5AM Ventures; Versant Ventures; Apposite Capital; SR One; MS Ventures; and Aravis Venture. RuiYi also hired Erik Karrer as...
07:00 , May 27, 2013 |  BioCentury  |  Finance

Value reality check

Europe's economic crisis has created a new reality. Austerity measures at the national level have placed an even higher premium than in the past on controlling healthcare costs, resulting in an increasingly tough reimbursement environment...
07:00 , May 20, 2013 |  BioCentury  |  Finance

Merck Serono's earnest money

Four years after launching a strategic venture fund, the Merck Serono S.A. unit of Merck KGaA is making a long-term commitment with an infusion of €60 million ($77.8 million). While the fund's focus will remain...
08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Evergreen seedlings

Syncona Partners ' first deal is an example of exactly what The Wellcome Trust said its new venture fund would do - exploit its freedom from traditional VC time horizons to invest in early stage...